R. Todd Reilly - Concepedia

Author

R. Todd Reilly

Johns Hopkins University

Also Known As

R T Reilly, R Todd Reilly, R. Todd Reilly, R.Todd Reilly, Richard T Reilly

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Cancer Center University of South Carolina

About

R. Todd Reilly is an author at Johns Hopkins University specializing in medicine, radiation oncology, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.1K
2	Immunology	7	7	1.1K
3	Cell Biology	5	5	554
4	Pathology	2	2	111
5	Allergy	1	1	459

R. Todd Reilly

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Jean-Pascal Machiels, R. Todd Reilly, Leisha A. Emens, PubMed ImmunologyImmunoeditingImmunologic MechanismImmune Cell TherapyImmune System	2001	459
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response Anne M. Ercolini, Brian H. Ladle, Elizabeth A. Manning, The Journal of Experimental Medicine	2005	396
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. R. Todd Reilly, Morris B.C. Gottlieb, Anne M. Ercolini, PubMed Knockout MouseRadiation OncologyCancer ImmunosurveillanceMammary Gland DevelopmentT Cells	2000	216
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. R. Todd Reilly, Jean-Pascal Machiels, Leisha A. Emens, PubMed ImmunologyNeu-n MiceImmunologic MechanismImmunotherapyTumor Biology	2001	152
OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen Satoshi Murata, Brian H. Ladle, Peter Kim, The Journal of Immunology	2006	105
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/ <i>neu</i> -Transgenic Mice Matthew E. Wolpoe, Eric R. Lutz, Anne M. Ercolini, The Journal of Immunology	2003	104
Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice Anne M. Ercolini, Jean-Pascal H. Machiels, Yi Cheng Chen, The Journal of Immunology	2003	94
Ductal Access for Prevention and Therapy of Mammary Tumors Satoshi Murata, Scott L. Kominsky, Mustafa Vali, Cancer Research	2006	90
Chemotherapy: friend or foe to cancer vaccines? Leisha A. Emens, Jean‐Pascal Machiels, R. Todd Reilly, PubMed ImmunologyPathologyImmunotherapyCancer ChemotherapySynthetic Immunology	2001	79
OX40 costimulation can abrogate Foxp3<sup>+</sup> regulatory T cell‐mediated suppression of antitumor immunity Naomi Kitamura, Satoshi Murata, Tomoyuki Ueki, International Journal of Cancer Ox40 CostimulationAdaptive Immune SystemT-regulatory CellImmune RegulationImmunology	2009	77

Page 1